JAK2^V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

References

• Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato L N, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–232
   PubMed Web of Science ®Google Scholar
• Harrison C N. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005; 130: 153–165
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R, Pereira D L, Hoagland H C. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001; 76: 22–28
   PubMed Web of Science ®Google Scholar
• Wolanskyj A P, Schwager S M, McClure R F, Larson D R, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81: 159–166
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93: 1645–1651
   PubMed Web of Science ®Google Scholar
• Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
   PubMed Web of Science ®Google Scholar
• Levine R L, Wadleigh M, Cools J, Ebert B L, Wernig G, Huntly B J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic J P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser A S, Teo S S, Tiedt R, Passweg J R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790
   PubMed Web of Science ®Google Scholar
• Schafer A I. Molecular basis of the diagnosis and treatment of polycythemia and essential thrombocythemia. Blood 2006; 107: 4214–4222
   PubMed Web of Science ®Google Scholar
• Campbell P J, Scott L M, Buck G, Wheatley K, East C L, Marsden J T, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953
   PubMed Web of Science ®Google Scholar
• Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849
   PubMed Web of Science ®Google Scholar
• Wong R S, Cheng C K, Chan N P, Cheng S H, Wong W S, Lau K M, et al. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol 2008; 141: 902–904
   PubMed Web of Science ®Google Scholar
• Dahabreh I J, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33: 67–73
   PubMed Web of Science ®Google Scholar
• Ziakas P D. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008; 93: 1412–1414
   PubMed Web of Science ®Google Scholar
• Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39
   PubMed Web of Science ®Google Scholar
• Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato N L, et al. The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999; 104: 730–737
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114–124
   PubMed Web of Science ®Google Scholar
• Quentmeier H, MacLeod R AF, Zaborski M, Drexler H G. Jak2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471–476
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson R A, Lasho T L, Finke C M, Gangat N, Wolanskyj A P, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–2284
   PubMed Web of Science ®Google Scholar
• Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132: 244–245
   PubMed Web of Science ®Google Scholar
• Campbell P J, Green A R. The myeloproliferative disorders. N Engl J Med 2006; 335: 2452–2466
   Web of Science ®Google Scholar
• Jones A V, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168
   PubMed Web of Science ®Google Scholar
• Hsiao H H, Yang M Y, Liu Y C, Lee C P, Yang W C, Liu T C, et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007; 35: 1704–1707
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki J H. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007; 21: 1097–1099
   PubMed Web of Science ®Google Scholar
• Wolanskyj A P, Lasho T L, Schwager S M, McClure R F, Wadleigh M, Lee S J, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213
   PubMed Web of Science ®Google Scholar
• Carobbio A, Antonioli E, Guglielmelli P, Vannucchi A M, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26: 2732–2736
   PubMed Web of Science ®Google Scholar
• Kralovics R, Teo S S, Buser A S, Brutsche M, Tiedt R, Tichelli A, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106: 3374–3376
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, Della Porta M G, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34 + cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–3682
   PubMed Web of Science ®Google Scholar
• Michiels J J, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet H H. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32: 589–604
   PubMed Web of Science ®Google Scholar